Corporate

uBriGene congratulates strategic partner InnoVec Biotherapeutics on FDA clearance of IND for IVB103, an AAV-based gene therapy

GERMANTOWN, Md., August 7, 2024 - uBriGene Biosciences (uBriGene) , a global CDMO leader, is excited to announce that its strategic...

Join uBriGene Biosciences to discover the future of biotech at BIO San Diego Jun 03 - 06!

Get ready for an electrifying experience at the BIO International Convention — the largest and most comprehensive event for...

uBriGene's showcase at ISCT2024 Vancouver May 29 - Jun 1

We are delighted to announce that uBriGene will exhibit at the International Society for Cell and Gene Therapy (ISCT) 2024 conference. As...

uBriGene will exhibit at ASGCT2024 this May 7 – 11 in Baltimore

We’re excited to share that uBriGene will be participating in ASGCT2024 with an assortment of engaging activities. We will showcase...

uBriGene (Boston) Biosciences completed the transaction with Mustang Bio, Inc. (Nasdaq: MBIO)

uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract...

Cell and gene therapy CDMO targets North American growth with major US acquisition

uBriGene Biosciences Inc. (uBrigene), a cell & gene therapy contract development and manufacturing organization (CDMO), is expanding into...

uBriGene Biosciences Inc. closes 150 million CNY (20 million USD) Series C+ round

uBriGene Biosciences Inc. has closed a 150 million CNY (20 million USD) Series C+ financing round. It was completed just half a year...

uBriGene Biosciences completes several hundred million yuan Series C round funding

uBriGene Biosciences Inc. completes several hundred million yuan Series C round funding, focusing on global cell & gene therapy and...

Canada